The Prevalence and Prognostic Value of BRAFV600E Mutation in Papillary Thyroid Cancer


Creative Commons License

Al-Maaitah A., Alsmady M., Dmour S., Alsmady D., Al-Alwan A., Younis M., et al.

International Journal of Human and Health Sciences (IJHHS), cilt.3, ss.223-230, 2019 (Diğer Kurumların Hakemli Dergileri)

  • Cilt numarası: 3 Konu: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.31344/ijhhs.v3i4.106
  • Dergi Adı: International Journal of Human and Health Sciences (IJHHS)
  • Sayfa Sayısı: ss.223-230

Özet

Objective: B-type Raf kinase (BRAF)V600E mutation in papillary thyroid cancer (PTC) has variable prevalence worldwide and it is hypothesized to worsen tumor prognosis. This study was conducted to investigate the prevalence of BRAFV600E mutation among PTC patients and to find out its prognostic impact measured by its association with various clinicopathologic features, recurrence, and mortality. Methods: This is a retrospective study that included 123 PTC patients who underwent thyroidectomy at Jordan University Hospital between January 2010 and December 2015. They were followed up over a mean of 18 months (range: 4-72). BRAFV600E mutation was analyzed by direct sequencing. A p value less than 0.05 was defined as statistically significant. Results: Twenty three out of 123 (18.7%) PTC patients were BRAFV600E mutation positive. BRAFV600E- mutant patients were more likely to have larger tumor size (1.8 vs 2.5 cm, p=0.040), to present with lymph node metastasis (LNM) (41.2% vs 82.4%, p=0.002), and to develop recurrence (1 vs 3, p=0.0003). Moreover, tumor recurrence which was recorded in 4 patients was significantly associated with LNM (p=0.038). Cancer-specific mortality rate was null. Conclusion: BRAFV600E mutation rate in PTC was low relative to world-wide prevalence. BRAFV600E mutation has prognostic value for PTC management. However, its cost-effectiveness should be revised. Further larger prospective studies in the region are recommended